{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:12:09Z","timestamp":1739164329708,"version":"3.37.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/jcp.0b013e31819a6995","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T12:53:34Z","timestamp":1242910414000},"page":"117-123","source":"Crossref","is-referenced-by-count":12,"title":["Changes in Neurocognitive Function in Patients With Schizophrenia After Starting or Switching to Amisulpride in Comparison With the Normal Controls"],"prefix":"10.1097","volume":"29","author":[{"given":"Yong Min","family":"Ahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul-Eung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae-Yeob","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Youn","family":"Jun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Sook","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Won","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel S.-H.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Sik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00213-002-1053-y","article-title":"The effects of second generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.","volume":"162","author":"Weiss","year":"2002","journal-title":"Psychopharmacology"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/00207450490430552","article-title":"Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors?","volume":"114","author":"Tyson","year":"2004","journal-title":"Int J Neurosci"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1440-1819.2006.01534.x","article-title":"Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics.","volume":"60","author":"Tyson","year":"2006","journal-title":"Psychiatry Clin Neurosci"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia.","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics.","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":"The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.","volume":"25","author":"Keefe","year":"1999","journal-title":"Schizophr Bull"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/appi.ajp.159.6.1018","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.","volume":"159","author":"Bilder","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","article-title":"Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff?","volume":"26","author":"Green","year":"2000","journal-title":"Schizophr Bull"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1034\/j.1600-0447.2000.00016.x","article-title":"Compliance with antipsychotic treatment.","volume":"102","author":"Oehl","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia.","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr Bull"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.npp.1300626","article-title":"Cognitive improvements in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs. amisulpride.","volume":"30","author":"Wagner","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1017\/S1461145704004134","article-title":"How do we choose between atypical antipsychotics? The advantages of amisulpride.","volume":"7","author":"Mortimer","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of Amisulpride, an atypical D2\/D3 receptor antagonist with both presynaptic and limbic selectivity.","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/026988110001400206","article-title":"The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers.","volume":"14","author":"Legangneux","year":"2000","journal-title":"J Psychopharmacol"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archpsyc.64.10.1115","article-title":"Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?","volume":"64","author":"Goldberg","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00004850-200015010-00002","article-title":"Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia.","volume":"15","author":"Colonna","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1176\/appi.ajp.157.4.549","article-title":"Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates.","volume":"157","author":"Bilder","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1097-4679(199708)53:5<517::AID-JCLP14>3.0.CO;2-H","article-title":"Expanded norms for the Controlled Oral Word Association Test.","volume":"53","author":"Summerall","year":"1997","journal-title":"J Clin Psychol"},{"key":"R24-3-20210128","first-page":"286","article-title":"L'examen psychologique dans les cas d'encephalopathie traumatique.","volume":"28","author":"Rey","year":"1941","journal-title":"Arch Psychol"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1176\/ajp.156.9.1342","article-title":"Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia.","volume":"156","author":"Gold","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1348\/014466500163301","article-title":"The National Adult Reading Test as a measure of premorbid IQ in schizophrenia.","volume":"39","author":"Russell","year":"2000","journal-title":"Br J Clin Psychol"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1076\/jcen.20.3.339.822","article-title":"Practice effects during repeated administrations of memory tests with and without alternate forms.","volume":"20","author":"Benedict","year":"1998","journal-title":"J Clin Exp Neuropsychol"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/arclin\/10.3.241","article-title":"Practice effects with the NIMH AIDS abbreviated neuropsychological battery.","volume":"10","author":"McCaffrey","year":"1995","journal-title":"Arch Clin Neuropsychol"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF02214762","article-title":"Issues associated with repeated neuropsychological assessments.","volume":"5","author":"McCaffrey","year":"1995","journal-title":"Neuropsychol Rev"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.acn.2006.06.002","article-title":"The California Verbal Learning Test-second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms.","volume":"21","author":"Woods","year":"2006","journal-title":"Arch Clin Neuropsychol"},{"key":"R32-3-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0920-9964(02)00425-5","article-title":"Neuropsychological practice effects and change detection in people with schizophrenia.","volume":"62","author":"Beglinger","year":"2003","journal-title":"Schizophr Res"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/arclin\/5.4.405","article-title":"Alternate forms of the AVLT: a procedure and test for form equivalency.","volume":"5","author":"Shapiro","year":"1990","journal-title":"Arch Clin Neuropsychol"},{"key":"R34-3-20210128","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/sj.npp.1300216","article-title":"Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds.","volume":"28","author":"Weickert","year":"2003","journal-title":"Neuropsychopharmacology"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200904000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T16:40:51Z","timestamp":1739119251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200904000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31819a6995","relation":{},"ISSN":["0271-0749"],"issn-type":[{"type":"print","value":"0271-0749"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}